Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Naproxen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 0.97 |
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.97 |
| ▸ | AKR1C3 | P42330 | 11/20 | 0.97 |
| ▸ | AKR1C2 | P52895 | 11/20 | 0.97 |
| ▸ | TSHR | P16473 | 2/20 | 0.97 |
| ▸ | CDC42 | P60953 | 1/20 | 0.97 |
| ▸ | RAC1 | P63000 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.63 |
| ▸ | APP | P05067 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naproxen SCHEMBL28999051 | 1.00 | AKR1C3 (0.97) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL7362 | 1.00 | AKR1C3 (0.97) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL3832769 | 0.98 | AKR1C3 (0.94) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL29350704 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL10029028 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL29359528 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL3046 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL616149 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL42434 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL215236 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000071122-A1 | STABILIZED COMPOSITION BASED ON PYRIDINYL-SULFINYL-BENZIMIDAZOLES AND PROCESS | PAR PHARMACEUTICAL, INC. (US) | 2000-11-30 | — | — | WO | claimed |
| EP-0977724-A1 | PROCESS FOR CHIRAL ENRICHMENT OF OPTICALLY ACTIVE CARBOXYLIC ACIDS, OR SALTS OR ESTERS THEREOF | ALBEMARLE CORPORATION (US) | 2000-02-09 | — | — | EP | claimed |
| WO-1998045240-A1 | PROCESS FOR CHIRAL ENRICHMENT OF OPTICALLY ACTIVE CARBOXYLIC ACIDS, OR SALTS OR ESTERS THEREOF | ALBEMARLE CORPORATION (US) | 1998-10-15 | — | — | WO | claimed |
| EP-1799195-B1 | GRANULES COMPRISING PARACETAMOL, AN NSAID AND A SUGAR ALCOHOL MADE BY MELT EXTRUSION | RECKITT BENCKISER HEALTHCARE (GB) | 2016-03-23 | — | — | EP | disclosed |
| EP-1804772-B1 | GRANULES COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY DRUG AND A SUGAR ALCOHOL MADE BY MELT EXTRUSION | RECKITT BENCKISER HEALTHCARE (GB) | 2011-10-05 | — | — | EP | disclosed |
| US-20080085308-A1 | Granules Comprising Paracetamol, a Nsaid and a Sugar Alchohol Made by Melt Extrusion | RECKITT BENCKISER HEALTHCARE (UK) LIMITED (GB) | 2008-04-10 | — | — | US | disclosed |
| US-20070254028-A1 | Granules Comprising a Nsaid and a Sugar Alcohol Made by Melt Extrusion | RECKITT BENCKISER HEALTHCARE (UK) LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| US-20070184078-A1 | Packaging system | ANDRX CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
| US-20050004118-A1 | Prodrugs of non-steroidal anti-inflammatory and carboxylic acid containing compounds | JILANI JAMAL A (JO) | 2005-01-06 | — | — | US | disclosed |
| US-20030060465-A1 | Prodrugs of non-steroidal anti-inflammatory and carboxylic acid containing compounds | SPECIALIZED PHARMACEUTICAL RESEARCH LTD. CO. (JO) | 2003-03-27 | — | — | US | disclosed |
| EP-1231209-A1 | Prodrugs of non-steroidal anti-inflammatory and carboxylic acid containing compound | Specialized Pharmaceutical Research Ltd. Co. (JO) | 2002-08-14 | — | — | EP | disclosed |
| WO-2000071122-A1 | STABILIZED COMPOSITION BASED ON PYRIDINYL-SULFINYL-BENZIMIDAZOLES AND PROCESS | PAR PHARMACEUTICAL, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| EP-0780358-B1 | A process for the resolution of 6-methoxy-alpha-methyl-2-naphthaleneacetic racemic acid into its enantiomers | FARCHEMIA SRL (IT) | 2000-07-19 | — | — | EP | disclosed |
| EP-0977724-A1 | PROCESS FOR CHIRAL ENRICHMENT OF OPTICALLY ACTIVE CARBOXYLIC ACIDS, OR SALTS OR ESTERS THEREOF | ALBEMARLE CORPORATION (US) | 2000-02-09 | — | — | EP | disclosed |
| US-5936118-A | Process for chiral enrichment of optically active carboxylic acids or salts or esters thereof | ALBEMARLE CORPORATION (US) | 1999-08-10 | — | — | US | disclosed |
| WO-1998045240-A1 | PROCESS FOR CHIRAL ENRICHMENT OF OPTICALLY ACTIVE CARBOXYLIC ACIDS, OR SALTS OR ESTERS THEREOF | ALBEMARLE CORPORATION (US) | 1998-10-15 | — | — | WO | disclosed |
| US-5760287-A | Process for the resolution of 6-methoxy-alpha-methyl-2-naphthaleneacetic racemic acid into its enantiomers | FARCHEMIA S.R.L. (IT) | 1998-06-02 | — | — | US | disclosed |
| EP-0780358-A1 | A process for the resolution of 6-methoxy-alpha-methyl-2-naphthaleneacetic racemic acid into its enantiomers | FARCHEMIA S.r.l. (IT) | 1997-06-25 | — | — | EP | disclosed |
| US-4625054-A | Process for the resolution of (+)-6-methoxy-α-methyl-2-naphthaleneacetic acid into the corresponding enantiomers | SECIFARMA S.P.A. (IT) | 1986-11-25 | — | — | US | disclosed |
| US-4132804-A | 2-(6-METHOXY-2-NAPHTHYL)PROPIONIC ACID | THE UPJOHN COMPANY (US) | 1979-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004118-A1 | Prodrugs of non-steroidal anti-inflammatory and carboxylic acid containing compounds | HCAR2, NONO, ALOX15 | PTGS2 14/4885PTGS1 11/4885AKR1C3 58/4885 |
| US-20030060465-A1 | Prodrugs of non-steroidal anti-inflammatory and carboxylic acid containing compounds | NONO, CCNO, HCAR2 | PTGS2 14/4885PTGS1 10/4885AKR1C3 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.